Spots Global Cancer Trial Database for Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Official Title: A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Study ID: NCT03869762
Study Description
Brief Summary: Open-label phase II multi-centre single arm study of Denosumab in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
Detailed Description: This is an open-label phase II multi-centre single arm study of Denosumab in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Galway University Hospital, Galway, Connacht, Ireland
Sligo University Hospital, Sligo, Connacht, Ireland
Adelaide and Meath incorporating National Children's Hopsital, Dublin 24, Leinster, Ireland
St. Vincent's Hospital, Dublin 4, Leinster, Ireland
Cork University Hospital, Cork, Munster, Ireland
University Hospital Limerick, Limerick, Munster, Ireland
University Hospital Waterford, Waterford, Munster, Ireland
Contact Details
Name: Prof Ray McDermott
Affiliation: The Adelaide and Meath Hospital, Dublin, incorporating the National Children's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
